The 2025–2026 metabolic landscape is defined by a massive shift in patient access: the transition from weekly injections to daily oral small molecules. As of March 2026, the oral GLP-1 weight loss drugs 2026 pipeline has achieved “injectable-like” efficacy, promising to expand the total addressable market to patients who are needle-averse or lack refrigeration access.
While Novo Nordisk launched the first wave with the FDA-approved Wegovy pill in early 2026, the market is quickly becoming a three-way race between Eli Lilly, Structure Therapeutics, and Viking Therapeutics.
Eli Lilly’s Orforglipron: The Impending FDA Decision
Eli Lilly is currently in the final stages of regulatory review for orforglipron, its once-daily non-peptide GLP-1 receptor agonist. Following a receipt of an FDA Commissioner’s National Priority Voucher, the target action date is now set for April 10, 2026. Unlike peptide-based orals, orforglipron is a small molecule, which allows for simpler manufacturing and higher scalability.
- Inventory Strategy: Lilly has reportedly amassed a $1.5 billion pre-launch inventory to prevent the shortages that plagued early Zepbound launches.
- Clinical Performance: In the ATTAIN-MAINTAIN trial, patients switching from injectables to oral orforglipron maintained their weight loss over 52 weeks with minimal regain.
Structure Therapeutics: Breaking Records with Aleniglipron
The most significant clinical breakthrough of March 2026 came from Structure Therapeutics. On March 16, 2026, the company reported topline data from its Phase 2 ACCESS II trial for aleniglipron.
Key Data from Phase 2 ACCESS II (March 2026)
| Metric | Result (180mg Dose) | Clinical Context |
|---|---|---|
| Mean Weight Loss | 16.3% (Placebo-Adjusted) | Highest reported for an oral GLP-1 to date. |
| Duration | 44 Weeks | No evidence of a weight loss plateau. |
| Discontinuation Rate | 2.0% – 3.4% | Managed via a low 2.5mg starting dose titration. |
Structure Therapeutics plans to initiate its pivotal Phase 3 program for aleniglipron in the second half of 2026, positioning itself as a “best-in-class” oral contender.
Viking Therapeutics: The Oral VK2735 Advantage
Viking Therapeutics has emerged as a formidable competitor with oral VK2735, a dual GLP-1/GIP agonist. Following a successful End-of-Phase 2 meeting with the FDA in late 2025, Viking announced on February 11, 2026, that it will advance the oral formulation into Phase 3 trials in Q3 2026. The oral tablet previously demonstrated 12.2% weight loss after just 13 weeks of daily dosing, suggesting high potency in a short window.
References
- Lilly Investor Relations. (2026). Q4 2025 Financial Results and 2026 Outlook.
- Structure Therapeutics. (2026). Topline Data from Phase 2 ACCESS II Trial.
- Viking Therapeutics. (2026). Business Update and Phase 3 Initiation Timeline.